Safety and Effectiveness of Bronchial Thermoplasty When FEV1 Is Less Than 50%

Published:September 13, 2019DOI:


      Randomized clinical trials of bronchial thermoplasty (BT) were conducted in patients with a baseline FEV 1 greater than 50%. There is a paucity of data regarding BT in patients with more severe obstruction, and consequently these patients are often excluded from receiving BT. The purpose of this study was to compare safety and efficacy outcomes in a large cohort of patients with an FEV 1 less than 50% with those of a cohort of less obstructed patients.


      Consecutive patients with severe asthma were drawn from the Australian BT Registry. Patients were grouped into (1) those with a baseline prebronchodilator FEV 1 % predicted < 50% (n = 32) or (2) those with an FEV 1 ≥ 50% (n = 36). Adverse outcomes were defined as (1) remaining in hospital longer than the planned 24-hour admission posttreatment or (2) being readmitted to hospital for any cause within 30 days of a treatment. Efficacy outcomes were evaluated 6 months after BT.


      More severely obstructed patients were no more likely to have experienced any adverse event. Significant improvements in Asthma Control Questionnaire score, exacerbation frequency, reliever medication use, and requirement for daily oral steroids were observed in both groups, and were of a similar degree.


      This study demonstrates that BT can confidently be offered to patients with asthma with an FEV 1 that is 30% to 50% of predicted without risk of more frequent or more severe adverse events, and with the expectation of the same degree of response as patients with better lung function.

      Key Words


      ACQ ( Asthma Control Questionnaire), BT ( bronchial thermoplasty), ERS/ATS ( European Respiratory Society/American Thoracic Society)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dombret M.C.
        • Alagha K.
        • Philippe Boulet L.
        • et al.
        Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults.
        Eur Respir Rev. 2014; 23: 510-518
        • Global Initiative for Asthma
        Global strategy for asthma management and prevention. Updated 2017.
        • Castro M.
        • Rubin A.S.
        • Laviolette M.
        • et al.
        Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial.
        Am J Respir Crit Care Med. 2010; 181: 116-124
        • Cox G.
        • Thomson N.C.
        • Rubin A.S.
        • et al.
        Asthma control during the year after bronchial thermoplasty.
        N Engl J Med. 2007; 356: 1327-1337
        • Pavord I.D.
        • Cox G.
        • Thomson N.C.
        • et al.
        Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma.
        Am J Respir Crit Care Med. 2007; 176: 1185-1191
        • Chupp G.
        • Laviolette M.
        • Cohn L.
        • et al.
        other members of the PAS2 Study Group. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicenter studies.
        Eur Respir J. 2017; 50: 1700017
        • Doeing D.C.
        • Mahajan A.K.
        • White S.R.
        • Naureckas E.T.
        • Krishnan J.A.
        • Hogarth D.K.
        Safety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case series.
        J Asthma. 2013; 50: 215-218
        • Torrego A.
        • Sola I.
        • Munoz A.
        • et al.
        Bronchial thermoplasty for moderate or severe persistent asthma in adults [review].
        Cochrane Database Syst Rev. 2014; 3CD009910
        • Langton D.
        • Wang W.
        • Thien F.
        • Plummer V.
        The acute effects of bronchial thermoplasty on FEV1.
        Respir Med. 2018; 137: 147-151
        • James A.L.
        • Bai T.R.
        • Mauad T.
        • et al.
        Airway smooth muscle thickness in asthma is related to severity but not duration of asthma.
        Eur Respir J. 2009; 34: 1040-1045
        • Chung K.F.
        • Wenzel S.E.
        • Brozek J.L.
        • et al.
        International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.
        Eur Respir J. 2014; 43: 343-373
        • Juniper E.F.
        • Svensson K.
        • Mörk A.C.
        • Ståhl E.
        Measurement properties and interpretation of three shortened versions of the Asthma Control Questionnaire.
        Respir Med. 2005; 99: 553-558
        • Miller M.
        • Hankinson J.
        • Brusasco V.
        • et al.
        ATS/ERS Task Force. Standardisation of spirometry.
        Eur Respir J. 2005; 26: 319-338
        • Quanjer P.H.
        • Stanojevic S.
        • Cole T.J.
        • et al.
        Multi-ethnic reference values for spirometry for 3-95 year age range: the Global Lung Function 2012 equations.
        Eur Respir J. 2012; 40: 1324-1343
        • Torrego A.
        • Herth F.
        • Munoz A.
        • et al.
        Bronchial thermoplasty global registry: one year results [abstract].
        Eur Respir J. 2018; 52OA1921